Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

Many unique clinical challenges accompany the diagnosis and treatment of cardiovascular
disease (CVD) in people living with overweight/obesity. Similarly, physicians encounter …

Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …

In recent years, the field of venous thromboembolism has undergone numerous innovations,
starting from the recent discoveries on the role of biomarkers, passing through the role of …

This study integrated 5 United States healthcare claims databases to evaluate the risk of
recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …